全球TOP10藥企市值重塑

醫藥財經

2025/08/04

截至2025年8月1日美股收盤，全球TOP10藥企市值排名劇烈重塑。禮來、強生、艾伯維依次居前三，而諾和諾德因減肥藥市場受挫跌至第5，輝瑞因管線單一跌至第10。以下是醫藥財經AI的深度分析及關鍵驅動因素：一、市值排名劇變：諾和諾德隕落與艾伯維崛起1. 諾和諾德：從「歐洲市值之王」滑落至第六五市值暴跌60%：一年內市值從6350億美元峯值跌至2139億美元，蒸發超4000億美元。（見：突發！諾和諾德...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556587912"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556587912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556587912?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-04 08:18","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2556587912","market":"us","top_or_hot":-1,"title":"全球TOP10藥企市值重塑","media":"醫藥財經","content":"<div>\n<p>截至2025年8月1日美股收盤，全球TOP10藥企市值排名劇烈重塑。禮來、強生、艾伯維依次居前三，而諾和諾德因減肥藥市場受挫跌至第5，輝瑞因管線單一跌至第10。以下是醫藥財經AI的深度分析及關鍵驅動因素：一、市值排名劇變：諾和諾德隕落與艾伯維崛起1. 諾和諾德：從「歐洲市值之王」滑落至第六五市值暴跌60%：一年內市值從6350億美元峯值跌至2139億美元，蒸發超4000億美元。（見：突發！諾和諾德...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804092706a6d12d4d&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>全球TOP10藥企市值重塑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n全球TOP10藥企市值重塑\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">醫藥財經</strong><span class=\"h-time small\">2025-08-04 08:18</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>截至2025年8月1日美股收盤，全球TOP10藥企市值排名劇烈重塑。禮來、強生、艾伯維依次居前三，而諾和諾德因減肥藥市場受挫跌至第5，輝瑞因管線單一跌至第10。以下是醫藥財經AI的深度分析及關鍵驅動因素：一、市值排名劇變：諾和諾德隕落與艾伯維崛起1. 諾和諾德：從「歐洲市值之王」滑落至第六五市值暴跌60%：一年內市值從6350億美元峯值跌至2139億美元，蒸發超4000億美元。（見：突發！諾和諾德...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804092706a6d12d4d&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804092706a6d12d4d&s=b\">醫藥財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3581.USD","symbol_name":"Legg Mason ClearBridge - Value A Acc USD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804092706a6d12d4d&s=b","article_id":"2556587912","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804092706a6d12d4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2556587912","pubTimestamp":1754266738,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"截至2025年8月1日美股收盤，全球TOP10藥企市值排名劇烈重塑。諾和諾德股價暴跌超20%，市值蒸發近千億美元。表：2025年TOP10藥企市值動態變化對比結語此次市值洗牌不僅反映企業短期業績波動，更揭示醫藥行業新範式：技術代際差、政策定價權、新興市場絞殺成為估值三大核心變量。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","688235":"百济神州","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","AZN":"阿斯利康","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4585":"ETF&股票定投概念","PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","ONC":"百济神州","SG9999001176.USD":"United Global Healthcare Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","NVO":"诺和诺德","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","01276":"恒瑞医药","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","06160":"百济神州","BK4599":"减肥药","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4592":"伊斯兰概念","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LLY":"礼来","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","JNJ":"强生","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4007":"制药","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","MRK":"默沙东","BK4581":"高盛持仓","SG9999002224.SGD":"Allianz Global High Payout SGD"},"translate_title":"Reshaping the market value of the global TOP10 pharmaceutical companies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"688235":0.9,"01276":0.9,"PFE":0.9,"JNJ":0.9,"ONC":0.9,"MRK":0.9,"NVO":0.9,"AZN":0.9,"06160":0.9,"LLY":0.9},"content_text":"截至2025年8月1日美股收盤，全球TOP10藥企市值排名劇烈重塑。禮來、強生、艾伯維依次居前三，而諾和諾德因減肥藥市場受挫跌至第5，輝瑞因管線單一跌至第10。以下是醫藥財經AI的深度分析及關鍵驅動因素：一、市值排名劇變：諾和諾德隕落與艾伯維崛起1. 諾和諾德：從「歐洲市值之王」滑落至第六五市值暴跌60%：一年內市值從6350億美元峯值跌至2139億美元，蒸發超4000億美元。（見：突發！諾和諾德股價暴跌超20%，市值蒸發近千億美元。）直接導火索：2025年7月29日單日股價暴跌21%-24%，因下調全年業績指引（營收增速從13%-21%下調至8%-14%，利潤增速從16%-24%下調至10%-16%）。核心問題：GLP-1減肥藥主導地位被禮來取代，研發管線（如CagriSema減重效果不及預期）、產能短缺及醫保壓價風險疊加。2. 艾伯維：逆勢躍居第三艾伯維市值達3448億美元，Q2營收154.2億美元（超預期6.6%），免疫學產品Skyrizi（+62.2%）和Rinvoq（+41.8%）驅動增長，抵消Humira生物類似藥衝擊。神經科學業務（+24.2%）成為新支柱，全年EPS指引上調至$11.88-$12.087。3. 輝瑞：跌至第十，轉型困局延續市值僅1335億美元，新冠產品需求退潮後，創新管線青黃不接，2024年至今無重磅新藥上市。二、諾和諾德隕落的深層原因：GLP-1神話破滅1. 競爭格局顛覆：禮來完成技術反超從臨床數據層面，禮來Zepbound（替爾泊肽）減重效果（72周22.9%）逼近諾和諾德2026年上市的CagriSema（68周22.7%），且副作用更低。禮來直銷平台LillyDirect搶佔美國自費市場，而諾和諾德因產能短缺多次斷供，用户流失後難以迴流。2. 政策與價格雙殺醫保壓價：美國將Wegovy/Ozempic納入2027年醫保談判，參考首批藥品（如Januvia降價79%），面臨腰斬級降價風險。主動降價失效：諾和諾德將Wegovy價格降至499美元/月（降幅63%），但仍難敵仿製藥（200-400美元/月）及中國競品（信達生物同類藥價格僅其1/3）。3. 研發與管理危機新一代減肥藥CagriSema臨床數據不及預期，CEO更迭暴露戰略執行混亂。專利懸崖逼近：司美格魯肽核心專利2026年到期，百款GLP-1仿製藥即將上市。三、其他藥企進退之道禮來（7225億）：雖因諾和諾德拖累單日跌5.6%，但GLP-1雙靶點藥物+口服制劑技術領先，仍為行業第一。強生（4030億）：穩居第二，依賴多元化醫療業務（器械+製藥）抗風險。阿斯利康（2294億）：腫瘤藥奧希替尼與ADC藥物Enhertu驅動增長，但中國業務增速放緩（+5%）。默沙東（1991億）：Keytruda佔收入50%，但HPV疫苗在華暴跌55%，被迫裁員重組。四、趨勢總結：估值邏輯重構的三大信號1. GLP-1賽道從狂熱迴歸理性資本重新審視過度樂觀預期，頭部企業（諾和諾德、禮來）市值蒸發與產業鏈估值回調標誌泡沫出清。2. 多元化佈局成生存關鍵艾伯維（免疫學+神經科學）與強生（製藥+器械）因業務分散抗風險，而輝瑞、諾和諾德過度依賴單一品類遭遇重挫。3. 新興市場本土藥企崛起中國藥企如百濟神州（營收+55%）、恒瑞醫藥（4款新藥上市）憑藉創新與性價比衝擊全球市場，加速創新藥賽道價格內卷。表：2025年TOP10藥企市值動態變化對比結語此次市值洗牌不僅反映企業短期業績波動，更揭示醫藥行業新範式：技術代際差（如禮來對諾和諾德的超越）、政策定價權（醫保談判壓制利潤）、新興市場絞殺（中國藥企性價比戰略）成為估值三大核心變量。未來頭部藥企需在管線多元化、本地化支付策略及供應鏈韌性上重構競爭力，否則「神藥光環」終將淪為「估值陷阱」。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}